Literature DB >> 21426412

Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations.

Carsten Bergmann, Marion Wobser, Henner Morbach, Albrecht Falkenbach, Dietrich Wittenhagen, Lisa Lassay, Hagen Ott, Klaus Zerres, Herman J Girschick, Henning Hamm.   

Abstract

Digital clubbing is the most prominent feature in primary (PHO) and secondary (pulmonary) hypertrophic osteoarthropathy (HO). Homozygous and compound heterozygous germline mutations in the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene encoding the major prostaglandin PGE2 catabolizing enzyme have been recently described in familial PHO cases. Elevated prostaglandin levels in affected individuals with cytokine-mediated tissue remodelling and vascular stimulation may underlie PHO and associated features as hyperhidrosis, acroosteolysis, pachyderma, periostosis and arthritis. We present clinical and biochemical data of three unrelated PHO families with HPGD mutations. The truncating mutation c.175_176del was found in two of our families and in one of the recently described pedigrees, all of European origin. We present evidence that c.175_176del is a recurrent mutation rather than an ancient founder allele. Two novel heterozygous HPGD mutations, the nonsense mutation c.118G>T (p.Glu40X) and the missense mutation c.563C>T (p.Thr188Ile), could be identified in a third family. We postulate that all HPGD mutations constitute loss-of-function alleles due to protein truncation or missense changes that affect hydrogen bonds lining the 15-PGDH enzyme reaction cavity. Elevated prostaglandin levels may give rise to use of non-steroidal anti-inflammatory drugs; however, therapeutic strategies have not been reported to date. Naproxen treatment in one of our mutation-positive patients resulted in alleviation of pain caused by periostosis and arthritis as well as reduction in substantially elevated prostaglandin levels, while no significant effects on digital clubbing, hyperhidrosis and pachyderma were observed. Further experience with nonsteroidal anti-inflammatory drugs in PHO is awaited.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21426412     DOI: 10.1111/j.1600-0625.2011.01248.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  10 in total

1.  [Bronchial carcinoma and knee pain. Secondary hypertrophic osteoarthropathy].

Authors:  A Baranowski; M Hansen
Journal:  Unfallchirurg       Date:  2013-08       Impact factor: 1.000

2.  Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy.

Authors:  Zhenlin Zhang; Weibo Xia; Jinwei He; Zeng Zhang; Yaohua Ke; Hua Yue; Chun Wang; Hao Zhang; Jiemei Gu; Weiwei Hu; Wenzhen Fu; Yunqiu Hu; Miao Li; Yujuan Liu
Journal:  Am J Hum Genet       Date:  2011-12-22       Impact factor: 11.025

3.  Primary hypertrophic osteoarthropathy caused by homozygous deletion in HPGD gene in a family: changing clinical and radiological findings with long-term follow-up.

Authors:  Beyhan Tüysüz; Saliha Yılmaz; Özgür Kasapçopur; Tuğba Erener-Ercan; Emre Ceyhun; Kaya Bilguvar; Murat Günel
Journal:  Rheumatol Int       Date:  2014-05-12       Impact factor: 2.631

Review 4.  Primary hypertrophic osteoarthropathy: an update.

Authors:  Zeng Zhang; Changqing Zhang; Zhenlin Zhang
Journal:  Front Med       Date:  2013-01-23       Impact factor: 4.592

5.  Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance.

Authors:  Kishore Guda; Stephen P Fink; Ginger L Milne; Neil Molyneaux; Lakshmeswari Ravi; Susan M Lewis; Andrew J Dannenberg; Courtney G Montgomery; Shulin Zhang; Joseph Willis; Georgia L Wiesner; Sanford D Markowitz
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-16

6.  Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy.

Authors:  Na Li; Yuhang Ma; Yun Jiang; Li You; Yunhong Huang; Yongde Peng; Xiaoying Ding; Li Zhao
Journal:  Int J Endocrinol       Date:  2020-12-03       Impact factor: 3.257

7.  Clinical and biochemical characteristics of 12 Chinese primary hypertrophic osteoarthropathy patients with HPGD mutations.

Authors:  Qi Lu; Yang Xu; Shanshan Li; Zeng Zhang; Jiagen Sheng; Zhenlin Zhang
Journal:  Int J Biol Sci       Date:  2022-06-06       Impact factor: 10.750

8.  A novel mutation in the HPGD gene results in the unusual phenotype of palmoplantar keratoderma with digital clubbing and hyperhidrosis.

Authors:  Carla Stephan; Edith Hanna; Georges Nemer; Ossama Abbas; Mazen Kurban
Journal:  JAAD Case Rep       Date:  2018-10-12

9.  Novel SLCO2A1 mutations cause gender differentiated pachydermoperiostosis.

Authors:  Lijuan Yuan; Xihui Chen; Ziyu Liu; Dan Wu; Jianguo Lu; Guoqiang Bao; Sijia Zhang; lIfeng Wang; Yuanming Wu
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

10.  A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support.

Authors:  Amar Desai; Yongyou Zhang; Youngsoo Park; Dawn M Dawson; Gretchen A Larusch; Lakshmi Kasturi; David Wald; Joseph M Ready; Stanton L Gerson; Sanford D Markowitz
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.